Medical Devices

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

Biomerica's regulatory win in Egypt is more than a market entry; it's a strategic move to disrupt healthcare with low-cost, rapid diagnostic tools.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.

A breakthrough genetic therapy for ALS offers hope, but a split verdict from Canadian health agencies reveals the tough calculus of innovation versus cost.

Beyond its first-ever dividend, Covalon's true story is one of clinical innovation driving record sales, navigating market shifts, and funding global growth.

A landmark UK study reveals an AI diagnostic tool that predicts heart attacks with stunning accuracy and offers a £25 million lifeline to strained health budgets.

A Belgian med-tech firm is replacing a centuries-old procedure with an implantable pump, targeting a growing multi-billion dollar liver disease market.

With two key drug approvals, Sanofi isn't just treating rare diseases in China; it's executing a playbook that redefines market entry and dominance.

With FDA approval and $80M in funding, ProVerum’s ProVee system aims to disrupt the BPH treatment market by prioritizing safety and patient quality of life.

After major setbacks, a surge of innovative drugs is set to transform the ALS market. We decode the science, the money, and what it means for patients.

Nordson's record earnings reveal the high-tech backbone of premium goods and a resilient, behind-the-scenes investment in the high life.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

Benchmark Electronics poaches a key executive from rival Flex, signaling an aggressive push for commercial growth and supply chain resilience under new leadership.

A new campaign tackles undiagnosed kidney disease. But is it just public health, or a savvy strategy to reshape a multi-billion dollar market?

A new player enters the booming outpatient surgery market. DNV's CMS-approved accreditation challenges rivals with a unique continuous improvement model.

From water quality to workforce dynamics, leaders are tackling unseen threats to build a more resilient, efficient, and safer healthcare system for all.

Promising data for NuCana's NUC-7738 offers hope for tough-to-treat melanoma, but the biotech's financial health presents a critical hurdle.

With new clinical data and recent FDA approval, IceCure Medical's tumor-freezing tech is paving a new, less-invasive path for breast cancer treatment.

A new partnership aims to commercialize Arbli™, the first liquid losartan, leveraging a digital platform to solve patient adherence and capture market share.